Bevacizumab extends survival in advanced cervical cancer
Bevacizumab significantly extended survival by nearly 4 months in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard surgery and/or radiotherapy, according to the National Cancer Institute.
Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.